REMARKS

Applicant thanks Examiner Lambkin for discussions with the undersigned on April 2, 2007, and April 11, 2007. Examiner Lambkin noted in claim 51, no definitions for the variables R^{52} and R^{53} were present; and in claim 90 there is no antecedent basis for L^2 being a direct bond.

Applicant has amended the claims to include definitions for variables R^{52}, R^{53}, and correction of the definition for variable L^2. Support for the definitions of R^{52} and R^{53} is located on page 29, lines 1-7, of the specification as filed. Support for the correction to the L^2 variable is located on page 27, lines 19-24, of the specification as filed. Applicant has clarified the definition of R^{24} in the pending claims to include hydrogen as a substituent. Support for this amendment is replete in the examples contained in the specification as filed. Claim number 70 is cancelled as being rendered moot by the amendment to claim number 51, and claim number 115 is cancelled as being duplicative of claim number 114.

Applicant has enclosed herewith a Request for Continued Examination to submit a Supplemental Information Disclosure Statement for Examiner's consideration of International Publication Number WO 01/00206, Baldwin et al. Applicant respectfully directs the Examiner's attention to Example 47, on page 177, lines 23-29 of Baldwin et al.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application. It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Respectfully submitted,

Date: August 29, 2007

/ Rosemarie R. Wilk-Orescan; Reg. No. 45,220 /

Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969